AZTR News and Press, Azitra Inc From 08/26/25

A look at the top 10 most actives in the United States Allarity Therapeutics Inc. (ALLR) rose 122.0% to $2.0894 on volume of 156,874,466 shares Incannex Healthcare Inc. (IXHL) rose 13.8% to $0.8429 on volume of 120,020,692 shares Invivyd Inc. (IVVD) rose 52.8% to $0.8551 on volume of 86,034...

A look at the top 10 most actives in the United States Opendoor Technologies Inc (OPEN) fell 9.4% to $4.54 on volume of 745,442,840 shares Incannex Healthcare Inc. (IXHL) rose 25.9% to $0.7405 on volume of 407,362,847 shares OSR Holdings Inc. (OSRH) rose 96.1% to $1.01 on volume of 235,541,...

2025-08-12 10:05:28 ET More on Azitra Seeking Alpha’s Quant Rating on Azitra Financial information for Azitra Read the full article on Seeking Alpha For further details see: Azitra reports Q2 results

Azitra, Inc. Announces Q2 2025 Results and Provides Business Updates PR Newswire BRANFORD, Conn. , Aug. 11, 2025 /PRNewswire/ -- Azitra, Inc. ("Azitra") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies f...

2025-08-11 16:36:04 ET More on Azitra Seeking Alpha’s Quant Rating on Azitra Historical earnings data for Azitra Financial information for Azitra Read the full article on Seeking Alpha For further details see: Azitra to implement 1-for-6.66...

Azitra Reports Promising Safety Data from Phase 1b Trial in Netherton Syndrome PR Newswire Drug candidate ATR12-351 has been generally safe and well-tolerated with occasional, transient, mild to moderate symptoms at application site Trial is 50% enrolled; six patient...

Azitra, Inc. Announces Presentation at the 2025 BIO International Convention PR Newswire BRANFORD, Conn. , June 10, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative therapies ...

Azitra, Inc. Announces Presentation at ASCO 2025 Highlighting Clinical Trial Investigating ATR-04 for EGFRi-Associated Rash PR Newswire BRANFORD, Conn. , May 28, 2025 /PRNewswire/ -- Azitra, Inc. (NYSE American: AZTR), a clinical stage biopharmaceutical company f...

Azitra, Inc. to Present Abstract at American Society of Gene and Cell Therapy Highlighting Phase 1/2 Study Targeting Cancer Therapy-Associated Rash PR Newswire Azitra plans to dose first patient in a Phase 1/2 trial in the first half of 2025 for its precision dermatology c...

2025-05-14 11:35:23 ET More on Azitra Azitra enters share purchase agreement with Alumni Capital for up to $20M Seeking Alpha’s Quant Rating on Azitra Historical earnings data for Azitra Financial information for Azitra Read the full article ...